Drug · DIN 02455005
BRILINTA
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since June 13, 2016; first marketed June 13, 2016.
- Drug Identification Number (DIN)
- 02455005
- Company (DIN owner)
- Astrazeneca Canada IncMississauga, Ontario, Canada
- Schedule
- Prescription
- Dosage form
- Tablet
- Route
- Oral
- Therapeutic class (ATC)
- Ticagrelor B01AC24
- Class
- Human
- Record last updated
- March 2, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| TICAGRELOR | 60 MG |
Notices of Compliance
Health Canada approvals that name this DIN.
- May 30, 2016: NOC 18151Supplement to a New Drug Submission (SNDS) · To add a new strength of 60 mg tablet and new indication: patients with a history of myocardial infarction (mi occured at least one year ago) and a high risk of developing an atherothrombotic event
Other DINs named BRILINTA
- DIN 02368544 · Marketed